Neurodegenerative disease management最新文献

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS. 老年多发性硬化症患者接受干扰素β -1a或聚乙二醇干扰素β -1a治疗的结果

IF 2.3

Neurodegenerative disease management Pub Date : 2025-07-15 DOI: 10.1080/17582024.2025.2527558

Le H Hua, Carrie M Hersh, Lana Zhovtis Ryerson, Nick Belviso, Megan Vignos

引用次数: 0

Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases. 最近和正在进行的治疗左旋多巴诱导的运动障碍的试验：临床试验数据库综述。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-07-05 DOI: 10.1080/17582024.2025.2528557

Jawad Al-Kassmy, Mohammed Alsalmi, Woojin Kang, Michael Palayew, Philippe Huot

{"title":"Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases.","authors":"Jawad Al-Kassmy, Mohammed Alsalmi, Woojin Kang, Michael Palayew, Philippe Huot","doi":"10.1080/17582024.2025.2528557","DOIUrl":"https://doi.org/10.1080/17582024.2025.2528557","url":null,"abstract":"L-3,4-dihydroxyphenylalanine (Levodopa)-induced dyskinesia remains a condition for which there are few therapeutic options available. Fortunately, the past 5 years have seen the completion of several clinical trials, some of which yielded positive and encouraging results. Here, we performed a review of the clinical trials that were completed or for which outcomes were disclosed within the past 5 years. Promising results were obtained in Phase II trials with the serotonin type 1A (5-HT1A) agonist befiradol, the dopamine D3 receptor antagonist mesdopetam and the phosphodiesterase inhibitor CPL500036. In contrast, the metabotropic glutamate 4 (mGlu4) receptor negative allosteric modulator foliglurax and JM-010 (a combination of the 5-HT1A partial agonist buspirone and the and the 5-HT type 1B and 1D [5-HT1B/1D] agonist zolmitriptan) did not meet their endpoints in Phase II studies. Lastly, robot-assisted Repetitive Transcranial Magnetic Stimulation (rTMS) of the pre-supplementary motor area may be a promising non-pharmacological approach to alleviate dyskinesia.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fruits as a preventative strategy: exploring their role in neurodegenerative disease management. 水果作为一种预防策略：探索它们在神经退行性疾病管理中的作用。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-07-03 DOI: 10.1080/17582024.2025.2527543

Bhavani Sowndharya B, Rupesh K Gautam, Mathan Muthu C M, Bharath S, Vickram A S, Saravanan A, Gulothungan G, Hitesh Chopra

{"title":"Fruits as a preventative strategy: exploring their role in neurodegenerative disease management.","authors":"Bhavani Sowndharya B, Rupesh K Gautam, Mathan Muthu C M, Bharath S, Vickram A S, Saravanan A, Gulothungan G, Hitesh Chopra","doi":"10.1080/17582024.2025.2527543","DOIUrl":"https://doi.org/10.1080/17582024.2025.2527543","url":null,"abstract":"Fruits' popularity has grown due to their ability to protect against neurodegenerative illnesses and to be an important dietary component for good brain activity. This review focuses on fruits' potential for preventing such, taking into account their bioactive compounds and mode of action. It emphasizes the abundance of flavonoids, polyphenols, vitamins, and minerals found in berries, citrus, and other tropical fruits, which have been shown to reduce oxidative damage, prevent neuroinflammation, and improve synaptic plasticity. There is an extensive literature on the neuroprotective actions of compounds such as resveratrol, quercetin, and anthocyanins in neurogenesis and mitochondrial process functions. The review also mentions emerging literature with the gut-brain axis, where it underscores the way in which fruit-derived prebiotics and dietary fibers regulate gut microbiota, which in turn affects brain health. This study analyzes gaps by adopting a comprehensive approach to studying fruits' preventive power in the treatment of neurodegenerative illness. This study combines molecular biology, clinical trial, and dietary science findings to highlight the use of fruits in ordinary diets as a sustainable, natural way of promoting neuroprotection and slowing the course of NDs.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-12"},"PeriodicalIF":2.3,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival rates in frontotemporal dementia and Alzheimer's disease. 额颞叶痴呆和阿尔茨海默病的存活率

IF 2.3

Neurodegenerative disease management Pub Date : 2025-07-02 DOI: 10.1080/17582024.2025.2527553

David Foxe, James Muggleton, Sau Chi Cheung, Nicole Mueller, Rebekah M Ahmed, Manisha Narasimhan, James R Burrell, Yun Tae Hwang, Nicholas J Cordato, Olivier Piguet

{"title":"Survival rates in frontotemporal dementia and Alzheimer's disease.","authors":"David Foxe, James Muggleton, Sau Chi Cheung, Nicole Mueller, Rebekah M Ahmed, Manisha Narasimhan, James R Burrell, Yun Tae Hwang, Nicholas J Cordato, Olivier Piguet","doi":"10.1080/17582024.2025.2527553","DOIUrl":"https://doi.org/10.1080/17582024.2025.2527553","url":null,"abstract":"Aim: To evaluate the survival rates in well-characterized cohorts of frontotemporal dementia (FTD) subtypes - behavioral variant (bvFTD), progressive nonfluent aphasia (PNFA), and semantic dementia (SD) - and both typical (amnestic) and atypical (aphasic: logopenic progressive aphasia [LPA]) presentations of Alzheimer's disease (AD).Patients & methods: Three hundred and twenty-one participants (54 bvFTD, 26 PNFA, 22 SD, 20 LPA, 32 AD, 167 controls) were recruited. Patients underwent a comprehensive baseline assessment and annual reviews. Survival data were analyzed using Kaplan-Meier curves and Cox proportional hazard models.Results: Median survival from symptom onset was longest in SD (11.9 years) and shortest in LPA (7 years). Median survival for the bvFTD, PNFA, and AD groups was 8.7, 8.6, and 10 years, respectively. SD survival was significantly longer than PNFA and AD. Female sex was associated with shorter survival in LPA. Shorter symptom duration at baseline assessment was related to shorter survival in bvFTD, SD, LPA, and AD. Lower overall cognition in bvFTD, LPA, and AD, and worse functional outcomes in SD and AD at baseline were associated with shorter survival.Conclusions: Our findings demonstrate distinct survival patterns across FTD and AD subtypes. Demographic and presenting clinical features provide valuable prognostic insights for survival.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144541468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review of the impact of transcranial electrical stimulation (TES) on cognitive dysfunction in patients with multiple sclerosis. 经颅电刺激（TES）对多发性硬化症患者认知功能障碍影响的系统综述。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-27 DOI: 10.1080/17582024.2025.2520716

Mohammad Hossein Salemi, Mohammad Hossein Harirchian

{"title":"A systematic review of the impact of transcranial electrical stimulation (TES) on cognitive dysfunction in patients with multiple sclerosis.","authors":"Mohammad Hossein Salemi, Mohammad Hossein Harirchian","doi":"10.1080/17582024.2025.2520716","DOIUrl":"https://doi.org/10.1080/17582024.2025.2520716","url":null,"abstract":"Aim: This systematic review study aimed to evaluate the impact of TES on cognitive dysfunction in MS patients, aiming to consolidate current knowledge and explore its clinical applicability.Methods: A PRISMA-compliant search of MEDLINE, Scopus, and EMBASE identified randomized controlled trials (RCTs) and quasi-experimental studies assessing TES's impact on cognitive outcomes in MS. Data from nine studies were pooled using random-effects models, with subgroup analyses by stimulation type.Results: Meta-analysis revealed a small-to-moderate pooled effect of TES on cognitive function (standardized mean difference [SMD] = 0.62, 95% CI: 0.36-0.88, p < 0.001), though substantial heterogeneity was observed (I2 = 87.82%). Subgroup analysis showed tDCS improved cognitive outcomes (SMD = 0.32, p = 0.04), while tACS demonstrated a larger but non-significant effect (SMD = 1.39, p = 0.16). TES was generally safe, with transient side effects (e.g. scalp discomfort) reported.Conclusion: TES shows promise as an effective and safe intervention for cognitive dysfunction in MS patients. While improvements were observed in various cognitive domains, outcome variability underscores the need for further research to refine stimulation protocols.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-16"},"PeriodicalIF":2.3,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring prodrug approaches for Alzheimer's treatment: an overview. 探索阿尔茨海默病治疗的前药方法：综述。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-26 DOI: 10.1080/17582024.2025.2514990

Priya Kumari, Dileep Kumar, Shakuntala Chopade, Dipanjan Karati

引用次数: 0

Next-generation neurotherapeutics: nanotechnology, immunotherapy, and gene editing for neurodegenerative diseases. 下一代神经疗法：纳米技术、免疫疗法和神经退行性疾病的基因编辑。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-26 DOI: 10.1080/17582024.2025.2520707

Sameer Chaudhary, Sakshi Rawat, Sakshi Mathur, Asma Perveen, Abdul Hafeez, Anwar L Bilgrami, Ghulam Md Ashraf

{"title":"Next-generation neurotherapeutics: nanotechnology, immunotherapy, and gene editing for neurodegenerative diseases.","authors":"Sameer Chaudhary, Sakshi Rawat, Sakshi Mathur, Asma Perveen, Abdul Hafeez, Anwar L Bilgrami, Ghulam Md Ashraf","doi":"10.1080/17582024.2025.2520707","DOIUrl":"https://doi.org/10.1080/17582024.2025.2520707","url":null,"abstract":"Neurodegenerative disorders (NDDs), characterized by gradual decline of neuronal function and structure, present a major threat to global public health. Recent advances in neuropharmacology have opened promising avenues for novel therapeutic approaches. This review highlights promising neuropharmacological targets that may alleviate the debilitating effects of neurodegenerative disorders. This review examines established yet emerging molecular targets in neurodegeneration, including protein aggregation, synaptic dysfunction, oxidative stress, neuroinflammation, and Rho-associated protein kinase (ROCK) signaling. The review also explores ground-breaking therapeutic strategies that have transformed modern neuropharmacology. Recent advances in nanotechnology, gene therapy, immunotherapy, and in silico studies have revolutionized neurotherapeutics by enabling precise drug delivery, enhancing treatment efficacy, and facilitating personalized therapies. These innovations have also accelerated the discovery of novel compounds and improved prediction of therapeutic outcomes.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-20"},"PeriodicalIF":2.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Feasibility of expiratory muscle strength training in individuals with progressive supranuclear palsy. 进行性核上性麻痹患者呼气肌力训练的可行性。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-06 DOI: 10.1080/17582024.2025.2514994

Katya Villarreal-Cavazos, James C Borders, James A Curtis, Jordanna S Sevitz, Nora Vanegas-Arroyave, Michelle S Troche

{"title":"Feasibility of expiratory muscle strength training in individuals with progressive supranuclear palsy.","authors":"Katya Villarreal-Cavazos, James C Borders, James A Curtis, Jordanna S Sevitz, Nora Vanegas-Arroyave, Michelle S Troche","doi":"10.1080/17582024.2025.2514994","DOIUrl":"https://doi.org/10.1080/17582024.2025.2514994","url":null,"abstract":"Introduction: Dysphagia is common among individuals with Progressive Supranuclear Palsy (PSP). Expiratory muscle strength training (EMST) is a treatment used to increase expiratory muscle force production for airway protection deficits. To our knowledge, no studies have tested EMST in this population. The objective of this study was to determine the feasibility of EMST in individuals with PSP.Methods: Twenty-nine participants completed baseline measures of maximum expiratory pressure and underwent a trial session of EMST. EMST was considered feasible if participants were able to complete at least 10 repetitions at 30% of their maximum expiratory pressure. Qualitative analyses were also completed to investigate types and frequency of clinician support.Results: Twenty-seven participants (93%) successfully met the criteria for feasibility of EMST. Qualitative analysis revealed 20 individuals required clinician support with most requiring more than one type of assistance.Conclusions: EMST appears to be feasible for most people with PSP though additional clinician support is often required.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-5"},"PeriodicalIF":2.3,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longitudinal patterns of loss of independence in Parkinson disease. 帕金森病独立性丧失的纵向模式。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-04 DOI: 10.1080/17582024.2025.2514982

Tsung-Ying Lee, Lisa M Shulman, Ann L Gruber-Baldini, Julia F Slejko, Mathangi Gopalakrishnan, Eberechukwu Onukwugha

{"title":"Longitudinal patterns of loss of independence in Parkinson disease.","authors":"Tsung-Ying Lee, Lisa M Shulman, Ann L Gruber-Baldini, Julia F Slejko, Mathangi Gopalakrishnan, Eberechukwu Onukwugha","doi":"10.1080/17582024.2025.2514982","DOIUrl":"https://doi.org/10.1080/17582024.2025.2514982","url":null,"abstract":"Aim: To examine the longitudinal loss of independence (LOI) in Parkinson disease (PD) and introduce event visualization as a research tool.Methods: Early-stage PD patients seen by a movement disorders specialist from 2003-2020 were included. LOI, defined as needing help with activities of daily living (ADLs), was assessed using the modified Older Americans Resources and Services Daily Function Questionnaire. EventFlow software visualized LOI patterns.Results: The cohort included 296 patients (mean age 60.8; 61% male; 94% Hoehn & Yahr stages 1-2). At baseline, 91% were independent. LOI occurred in 133 patients for ≥ 1 ADL, and in 95 patients for ≥ 3 ADLs. Housework was the most frequent first ADL needing help (58 of 133), with a mean onset of 4.6 years. Among those with LOI, 57 (43%) regained independence at least once.Conclusion: LOI in PD shows both transient and persistent patterns. Event visualization may aid understanding of progression and support patient counseling.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary on taking medication as prescribed for multiple sclerosis: impact on relapses, disability, and healthcare costs. 简单的语言总结服用药物的规定多发性硬化症：对复发，残疾和医疗费用的影响。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-06-04 DOI: 10.1080/17582024.2025.2506949

Lilyana Amezcua, Terrie Livingston, Brooke Hayward, Jia Zhou, Mitzi J Williams

引用次数: 0